Platelet rich plasma (PRP) role in the treatment of baldness

Phase 2

Completed

• Conditions: Health Condition 1: null- Male type baldness

• Registration Number: CTRI/2018/05/014113
• Lead Sponsor: Institute of Medical sciences Banaras Hindu University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2018-02-24
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

1.All the patients not using topical minoxidil and finasteride for at least 6 months will be considered for PRP therapy.

2.Age group 20 â?? 60 years

3.Sex- Male

4.Mild to moderate AGA (Hamilton-Norwood score II-V) .

5.Patients willing to come for follow up every month for 5 months.

Exclusion Criteria

1.Patients not giving informed written consent, unable to understand the protocol and uncooperative patients.

2.Any inflammation, erythema or scarring over scalp except mild seborrheic dermatitis.

3.Patients who have history of malignancies, platelets disorders or bleeding disorders, anemia ( haemoglobulin of less than 10 gm/dl), bone marrow aplasia, diabetes, sepsis, and cancer.

4.Patients taking theses any of these medications-

i.Anti-coagulants â?? heparin, warfarin

ii.Anti-hypertensives â?? beta-blockers, ACE inhibitors hormones

iii.Anticonvulsants â?? valproic acid, carbamazepine, phenytoin, mood stabilizers Antidepressants, lithium

iv.Aspirin or any non-steroidal anti-inflammatory drugs two week prior to procedure.

v.Other medications cimetidine, retinoids (acitretin > isotretinoin), antithyroid drugs, cholesterol lowering drugs, interferons, amphetamines, bromocriptine, levodopa, some antipsychotic and anti-anxiety drugs, rarely tricyclic antidepressants such as amitriptyline

5.Patients who are known to be HIV, hepatitis B or C positive or otherwise immunocompromised.

6.Patients with a propensity for keloids

7.Patients on antiplatelet drugs like aspirin or non-steroidal anti-inflammatory drugs.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hair density <br/ ><br>Hamilton Norwood grading <br/ ><br>Patient self assessmentTimepoint: every month for 5 months

Secondary Outcome Measures

Name	Time	Method
Age <br/ ><br>sex <br/ ><br>occupation <br/ ><br>Education status <br/ ><br>Family History <br/ ><br>History of previous treatment for male type baldness <br/ ><br>Effect on personality <br/ ><br> <br/ ><br>Timepoint: Every month for 5 months